Contents

2 President’s Message
3 AMP Strategic Plan: Mission Statement, Vision Statement, Core Principles
5 AMP’s DEI Commitment
6 2022 Board of Directors & Committee Chairs
7 Organizational Relationships & International Affiliates
8 Public Policy and Advocacy
9 Innovation & Improved Patient Care
10 Membership and Annual Meeting Overview
11 Education Initiatives
12 Financial Statement
Dear Colleagues, Patients, and Friends,

As the ongoing SARS-CoV-2 pandemic fades from public attention, molecular professionals face some of our greatest challenges yet. We must help ensure that lessons learned during the pandemic about the critical importance of laboratory testing are not forgotten, and that our community’s ability to respond to future crises is not further hampered by unworkable regulatory oversight. Laboratory testing remains one of the greatest tools available for combatting the spread of infectious diseases; as such, our ability to innovate with the resources available (including staffing and supply chains) must be protected.

The “return to normal” has also led to happier developments for our community, including the resumption of in-person events, such as our annual meeting. At the face-to-face Board retreat earlier this year, our volunteer leadership appreciated the value of in-person discussion as they finalized our updated Core Principles, new Diversity, Equity and Inclusion (DEI) commitment, and Internal DEI Action Plan. These documents guide everything we do at AMP, and we remain committed to becoming the most open and welcoming professional society possible.

AMP is recognized for its unmatched expertise in all aspects of molecular diagnostics. For over 25 years, we’ve advanced the field through education, clinical practice, and advocacy. I encourage you to take advantage of our broad range of educational offerings, including annual meeting content, webinars and in-depth courses. You may also benefit from reading our freely available practice guidelines in The Journal of Molecular Diagnostics (JMD), the highest rated journal in its field.

If you’re a molecular professional but not yet a member, I encourage you to join us and experience all that AMP has to offer!

Sincerely,
Daniel E. Sabath, MD, PhD
University of Washington School of Medicine
Association of Molecular Pathology 2022 President
AMP’s strategic plan is dynamic. Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic goals and objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP’s Mission, Vision, and Core Principles.

The Association for Molecular Pathology is a not-for-profit scientific society that advances the clinical practice, science, and excellence of molecular and genomic laboratory medicine through education, innovation, and advocacy to enable highest quality health care.
The Association for Molecular Pathology provides global expertise in molecular testing that drives patient care.

- Quality Health Care Through Excellence in Clinical Molecular Testing
- Fostering a Diverse and Inclusive Global Community of Molecular Pathology Professionals
- Collaboration to Advance Molecular Pathology and Improve Equity in the Delivery of Molecular Laboratory Testing
- Advocacy that Advances the Field and Practice of Molecular Pathology, Protects Patients, and Improves the Adoption of Innovative Technologies and Tests
- Innovation to Transform Patient Care
AMP’s DEI Commitment

The Association of Molecular Pathology (AMP)’s mission is to enable the highest quality healthcare by advancing the clinical practice, science, and excellence of molecular and genomic laboratory medicine through education, innovation, and advocacy. We believe diversity, equity, and inclusion (DEI) is crucial to our efforts to serve our members and advance clinical care of patients. DEI will help ensure the long-term excellence of both the association and field of molecular and genomic laboratory medicine. At AMP, we define diversity, equity, and inclusion as:

- **Diversity**: Means all the ways that people are unique, which goes beyond gender to include race and ethnicity, sexual orientation, gender identity, age, religion, culture identity, disability, national origin, geographic location, scientific specialty and experience.

- **Equity**: Creates fair treatment and access for individuals by establishing policies and processes that both break down existing barriers and prevent the formation of new barriers for the success of members and staff, those they train and mentor, and ultimately the patients whom molecular and genomic laboratory medicine serve.

- **Inclusion**: Fosters an environment where all members and staff participate fully and are their authentic selves in their local work environment because they feel respected and valued.

Our community consists of healthcare professionals who are committed to helping people. Our field is best served by amplifying diverse voices in our community and including representation from across the spectrum of our community in everything we do. We will work together collaboratively across the healthcare field to address inequities for patients.
President – Daniel E. Sabath, MD, PhD
President-Elect; Awards and Strategic Opportunities Committee Chair – Laura J. Tafe, MD
Past President and Nominating Committee Chair – Antonia R. Sepulveda, MD, PhD
Secretary-Treasurer and Finance Committee Chair – Alexis B. Carter, MD
Clinical Practice Committee Chair – Jane Gibson, PhD
Economic Affairs Committee Chair – Samuel K. Caughron, MD
International Affairs Committee – Rami Mahfouz, MD, MPH
Membership Affairs Committee Chair – Shelby Melton, MD
Professional Relations Committee Chair – Eric Konnick, MD, MS
Program Committee Chair – Nirali Patel, MD
Publication & Communication Committee Chair – Patricia Tsang, MD
Training & Education Committee Chair – Alanna Church, MD
Genetics Subdivision Chair – Avni Santani, BS, PhD
Hematopathology Subdivision Chair – Eric Duncavage, MD
Infectious Diseases Subdivision Chair – Donna M. Wolk, PhD, D(ABMM)
Informatics Subdivision Chair – Jason D. Merker, MD, PhD
Solid Tumors Subdivision Chair – Anna Yemelyanova, MD
Executive Director – Mary Steele Williams, MNA, MT(ASCP)SM
Organizational Relationships

AMP maintains membership in the following organizations:

- BLOODPAC
- Cancer Leadership Council (CLC)
- Federation of American Societies for Experimental Biology (FASEB)
- Global Alliance for Genomic Medicine
- Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC)
- Intersociety Pathology Council (IPC)
- Intersociety Council for Pathology Information (ICPI) — Associate Member
- Personalized Medicine Coalition (PMC)
- World Health Organization International Agency for Research on Cancer (IARC)
- Association for Pathology Informatics (API)

AMP maintains relationships with many professional societies and patient groups.

AMP has formal representation in the following groups:

- Representative to ASCO CancerLinQ Steering Committee
- Cooperating Society of the American Board of Pathology (ABP)
- Steering Committee, NIST Genome in a Bottle Consortium
- Associate Member of the Intersociety Council for Pathology Information (ICPI)
- Sponsor of the National Academies Roundtable on Genomics and Precision Health
- Representatives to FNIH Biomarkers Consortium Steering Committees
- Representative to the College of American Pathology (CAP) Pathology Coding Caucus (PCC)
- Representative to the CAP Molecular Oncology and Genomic Medicine Resource Committees
- Food and Drug Administration Network of Experts
- Representative to FDA Systemic Harmonization and Interoperability Enhancement for Laboratory Data (SHIELD)
- Representatives to TRUU-Lab initiative

International Affiliates:

- The Hong Kong Society for Molecular Diagnostic Sciences
- The Korean Society for Laboratory Medicine
- The Molecular Pathology Association of India
- The German Society of Pathology
- Brazilian Society of Clinical Pathology and Laboratory Medicine
- The Italian Society of Pathology and Translational Medicine
- American University of Beirut Medical Center
- Middle East Molecular Biology Sources
AMP pursued a wide range of economic and policy initiatives in 2022, including:

- Released the well-received “Economics of Testing During a Public Health Emergency: Lessons learned from two years of COVID-19” white paper
- Hosted our second Annual Molecular Pathology Economics Summit
- Conducted PAMA Impact Survey
- Hosted a congressional briefing on gene patents
- Organized over 200 member meetings on Capitol Hill to express concern about the VALID Act, support CLIA modernization, and educate lawmakers on the value of laboratory developed testing procedures
- Issued 29 position statements and letters

For a full overview of AMP’s Advocacy efforts, please visit our Position Statements & Letters webpage.

www.amp.org/advocates
Innovation & Improved Patient Care

AMP published 3 clinical practice guidelines in 2022 and supported numerous efforts to provide member expertise during the pandemic response and advance other areas of patient care. AMP volunteers are also working on more than a dozen guidelines in progress and serving as external representatives on more than 30 projects with other scientific societies and institutions.

www.amp.org/innovates

TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. Published in the October 2022 issue of the Journal of Molecular Diagnostics. October; 24 (10): 1051-1063

An Educational Assessment of Evidence used for Variant Classification: A Report of the Association for Molecular Pathology. Published in the June 2022 issue of the Journal of Molecular Diagnostics. June; 24 (6): 555-565

Membership and Annual Meeting Overview

Total AMP membership grew for the 16th year in a row in 2022, surpassing **2,990 members** for the first time. While Regular Membership increased a satisfactory 4.7%, Associate Membership grew by an incredible 53.6% (and has grown by 117% since the introduction of free Associate Membership for trainees in 2021). AMP maintains a presence in **60 countries**.

2,990 MEMBERS
60 COUNTRIES

**1,403 PHYSICIANS**

**947 DOCTORAL SCIENTISTS**

**641 TECHNOLOGISTS, TRAINEES & OTHER**

After three long years, our community reunited in person at the 2022 Annual Meeting & Expo in Phoenix, Arizona. AMP went into planning for this event very cautiously, forecasting scaled-back attendance and exhibits in light of the ongoing pandemic. We were delighted to see a stronger-than-expected turnout, welcoming 1,790 scientific attendees and 195 exhibiting companies. We sincerely thank our community, exhibitors and corporate sponsors for their ongoing support of AMP events, and we look forward to resuming in-person international events at AMP Europe 2023 next year.
AMP’s in-person and digital education initiatives continued to be enhanced in 2022. The return to in-person events allowed for robust attendance at our “Get AMPed!” course, with registration reaching full capacity a full month before the start of the course. In the digital space, we attracted over 4,400 active users on our online learning platform, AMPED™ by offering over 275 hours of total recorded content, including 18 new webinars, two courses, 19 microlearning modules and over 40 hours of recordings from the 2022 AMP annual meeting. To learn more, visit educate.amp.org.
## Financial Statement

### STRATEGIC INITIATIVE

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advocacy</td>
<td>$(184,444)</td>
<td>$(505,376)</td>
<td>$(480,376)</td>
</tr>
<tr>
<td>Communications &amp; Outreach</td>
<td>$(202,822)</td>
<td>$(179,004)</td>
<td>$(140,059)</td>
</tr>
<tr>
<td>Education</td>
<td>$1,793,395</td>
<td>$248,073</td>
<td>$370,854</td>
</tr>
<tr>
<td>Innovation &amp; Improved Patient Care</td>
<td>$(129,286)</td>
<td>$(182,833)</td>
<td>$(369,395)</td>
</tr>
<tr>
<td>Membership &amp; Management Services</td>
<td>$(227,834)</td>
<td>$296,469</td>
<td>$140,944</td>
</tr>
</tbody>
</table>

### EXCESS REVENUE OVER EXPENSES

|                      | $1,049,009 | $(322,671) | $478,031      |

ANNUAL REPORT • 2022